Expression Characteristics of KAI1 and Vascular Endothelial Growth Factor and Their Diagnostic Value for Hepatocellular Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: We tried to investigate the expressioncharacteristics of KAI1, a suppressor of wide-spectrumtumor metastasis, and vascular endothelial growth factor(VEGF), the most common angiogenesis factor, and then toanalyze their diagnostic value for hepatocellular carcinoma(HCC). Methods: The protein and mRNA expression levelsof KAI1 or VEGF in HCC tissues and in self-controlled paracarcinomatissues were analyzed by Western blot and realtimepolymerase chain reaction, respectively. Serum levelsof KAI1 and VEGF in the patients with HCC, benign liverdisease or in healthy controls were quantitatively detected byenzyme-linked immunosorbent assay. Results: The expressionlevel of KAI1 was downregulated, while the expressionlevel of VEGF was upregulated in the tissues or serum of thepatients with HCC. The expression level of serum KAI1 inHCC patients was correlated with TNM staging, intrahepaticmetastasis, lymph node or peritoneal metastasis, and portalvein thrombus. In addition to the factors that were correlatedwith KAI1 expression, VEGF expression was also closely relatedto the α-fetoprotein level of the patients. The area underthe receiver operating characteristic curve for the diagnosisof HCC was 0.907 for KAI1 and 0.779 for VEGF. The sensitivityof serum KAI1 levels in the diagnosis of HCC was 86.96%;the accuracy was 83.06%, while the sensitivity, the accuracyand the negative predictive value were improved to 91.86%,84.68%, and 78.79% according to the combined detectionof KAI1 and VEGF, respectively. Conclusions: A combined detectionof KAI1 and VEGF may greatly improve the efficiencyof diagnosis and form a reliable panel of diagnostic markersfor HCC.
Abstract
Background/Aims: We tried to investigate the expressioncharacteristics of KAI1, a suppressor of wide-spectrumtumor metastasis, and vascular endothelial growth factor(VEGF), the most common angiogenesis factor, and then toanalyze their diagnostic value for hepatocellular carcinoma(HCC). Methods: The protein and mRNA expression levelsof KAI1 or VEGF in HCC tissues and in self-controlled paracarcinomatissues were analyzed by Western blot and realtimepolymerase chain reaction, respectively. Serum levelsof KAI1 and VEGF in the patients with HCC, benign liverdisease or in healthy controls were quantitatively detected byenzyme-linked immunosorbent assay. Results: The expressionlevel of KAI1 was downregulated, while the expressionlevel of VEGF was upregulated in the tissues or serum of thepatients with HCC. The expression level of serum KAI1 inHCC patients was correlated with TNM staging, intrahepaticmetastasis, lymph node or peritoneal metastasis, and portalvein thrombus. In addition to the factors that were correlatedwith KAI1 expression, VEGF expression was also closely relatedto the α-fetoprotein level of the patients. The area underthe receiver operating characteristic curve for the diagnosisof HCC was 0.907 for KAI1 and 0.779 for VEGF. The sensitivityof serum KAI1 levels in the diagnosis of HCC was 86.96%;the accuracy was 83.06%, while the sensitivity, the accuracyand the negative predictive value were improved to 91.86%,84.68%, and 78.79% according to the combined detectionof KAI1 and VEGF, respectively. Conclusions: A combined detectionof KAI1 and VEGF may greatly improve the efficiencyof diagnosis and form a reliable panel of diagnostic markersfor HCC.
참고문헌 (27)
- Barraud H, "Curative treatment of hepatocellular carcinoma", Rev Prat, 63, pp.229~233 (2013)
- Giannini EG, "Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it?", World J Gastroenterol, 19, pp.8808~8821 (2013)
- Gonzalez SA, "Diagnosis of hepatocellular carcinoma: role of tumor markers and liver biopsy", Clin Liver Dis, 15, pp.297~306 (2011)
- Tsai YC, "Dissecting the diverse functions of the metastasis suppressor CD82", KAI1, 2011, pp.585, 3166~3173
- Malik FA, "KAI-1", CD82, the molecule and clinical implication in cancer and cancer metastasis, 2009, pp.24, 519~530
- Zhang B, "KAI1", CD82 and cyclinD1 as biomarkers of invasion, metastasis and prognosis of laryngeal squamous cell carcinoma, 2013, pp.6, 1060~1067
- Yang JM, "KAI1 gene suppresses invasion and metastasis of hepatocellular carcinoma MHCC97-H cells in vitro and in animal models", Liver Int, 28, pp.132~139 (2008)
- Shibuya M, "Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases", J Biochem, 153, pp.13~19 (2013)
- Kanematsu M, "Magnetic resonance imaging and expression of vascular endothelial growth factor in hepatocellular nodules in cirrhosis and hepatocellular carcinomas", Top Magn Reson Imaging, 16, pp.67~75 (2005)
- Schoenleber SJ, "Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis", Br J Cancer, 100, pp.1385~1392 (2009)
- Ministry of Health of the People’s Republic of China, "Updated standards for the diagnosis and treatment of primary liver cancer", Zhonghua Gan Zang Bing Za Zhi, 20, pp.419~426 (2012)
- Zhang HJ, "Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma", World J Gastroenterol, 18, pp.5897~5904 (2012)
- Guo C, "Expression and clinical significance of p53, JunB and KAI1", CD82 in human hepatocellular carcinoma, 2009, pp.8, 389~396
- Xue YJ, "Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma", J Transl Med, 10, pp.200~ (2012)
- Li MQ, "CD82 gene suppression in endometrial stromal cells leads to increase of the cell invasiveness in the endometriotic milieu", J Mol Endocrinol, 47, pp.195~208 (2011)
- Zhong C, "Serum and tissue vascular endothelial growth factor predicts prognosis in hepatocellular carcinoma patients after partial liver resection", Hepatogastroenterology, 59, pp.93~97 (2012)
- Niizeki T, "Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy", J Gastroenterol, 47, pp.686~695 (2012)
- Knoener M, "Limited value of KAI1", CD82 protein expression as a prognostic marker in human gastric cancer, 2012, pp.32, 337~342
- Sengupta B, "Hepatocellular carcinoma: important biomarkers and their significance in molecular diagnostics and therapy", Curr Med Chem, 19, pp.3722~3729 (2012)
- Yu L, "The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis", Gynecol Oncol, 128, pp.391~396 (2013)
- Williams SC, "Circulating tumor cells", Proc Natl Acad Sci U S A, 110, pp.4861~ (2013)
- Park JJ, "KAI1 suppresses HIF-1α and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer", BMC Cancer, 12, pp.81~ (2012)
- Chigita S, "CD82 inhibits canonical Wnt signalling by controlling the cellular distribution of β-catenin in carcinoma cells", Int J Oncol, 41, pp.2021~2028 (2012)
- Yusenko MV, "Identifying CD82 (KAI1) as a marker for human chromophobe renal cell carcinoma", Histopathology, 55, pp.687~695 (2009)
- Chen Z, "Down-regulation of TM4SF is associated with the metastatic potential of gastric carcinoma TM4SF members in gastric carcinoma", World J Surg Oncol, 9, pp.43~ (2011)
- Zhang Y, "Serum vascular endothelial growth factor-C levels: a possible diagnostic marker for lymph node metastasis in patients with primary non-small cell lung cancer", Oncol Lett, 6, pp.545~549 (2013)
- Wang K, "Prognostic value of vascular endothelial growth factor expression in patients with prostate cancer: a systematic review with meta-analysis", Asian Pac J Cancer Prev, 13, pp.5665~5669 (2012)